DUBLIN--(BUSINESS WIRE)--The "Primary Hyperoxaluria - Pipeline Review, H2 2017" report has been added to Research and Markets' offering.
Primary Hyperoxaluria - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Primary Hyperoxaluria (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Primary Hyperoxaluria (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Primary Hyperoxaluria and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 1, 1 and 2 respectively.
Primary Hyperoxaluria (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Key Topics Covered:
- Primary Hyperoxaluria - Overview
- Primary Hyperoxaluria - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Products under Development by Companies
- Primary Hyperoxaluria - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Primary Hyperoxaluria - Companies Involved in Therapeutics Development
- Allena Pharmaceuticals Inc
- Alnylam Pharmaceuticals Inc
- Dicerna Pharmaceuticals Inc
- Intellia Therapeutics Inc
- OxThera AB
For more information about this report visit https://www.researchandmarkets.com/research/4jpttq/primary